PayaVax G79 is an innovative inactivated vaccine designed as a bivalent solution to protect poultry against Newcastle Disease Genotype VII (GVII) and Avian Influenza H9N2. This vaccine is developed from local virus strains and produced in accordance with international standards, including GMP (Good Manufacturing Practices) principles. The first bivalent vaccine produced in Iran Effectively stimulates the immune system Long-lasting immunity Produced according to global standards Approved by the Iranian Veterinary Organization

PayaVax G-VII is an inactivated monovalent vaccine developed to provide immunity in poultry against highly virulent Newcastle Disease caused by Genotype G-VII. This vaccine is produced using a local virus strain and manufactured in compliance with international standards, including GMP (Good Manufacturing Practices) guidelines. Effective immunity Flexible application Long-lasting protection Manufactured according to international standards Approved by the Iranian Veterinary Organization

PayaVax H9 is a monovalent inactivated vaccine designed to induce immunity in poultry against avian influenza caused by the H9N2 subtype. This vaccine is produced using a locally isolated virus strain and is manufactured in compliance with international standards, including Good Manufacturing Practices (GMP). Key Features: Effective immunity Optimized formulation Long-lasting protection Produced according to global standards Approved by the Veterinary Organization